US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

8.75

-4.0500-31.64%

Post-market: 8.800.0500+0.57%19:56 EST

Volume:6.50M

Turnover:63.62M

Market Cap:472.84M

PE:-3.85

High:12.69

Open:12.69

Low:8.52

Close:12.80

52wk High:33.68

52wk Low:5.14

Shares:54.04M

Float Shares:31.42M

Volume Ratio:2.23

T/O Rate:20.70%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2740

EPS(LYR):-5.5835

ROE:-40.80%

ROA:-28.15%

PB:1.25

PE(LYR):-1.57

Loading ...

Overview Company News Filings

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Evercore ISI Remains a Buy on Upstream Bio, Inc. (UPB)

Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential

BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy

Upstream Bio Reports Mixed Results in Phase 2 Data for Asthma Treatment

Upstream Bio Shares Plunge 20% Premarket After Co Reports Mid-Stage Asthma Drug Trial Data

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners

Upstream Bio Reports Positive Phase 2 Severe Asthma Data

BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study

Upstream Bio Inc - Verekitug Well Tolerated With Favorable Safety Profile

THOMSON REUTERS

Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study

THOMSON REUTERS

Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma

THOMSON REUTERS

Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO)

Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials

Upstream Bio CEO to Present at J.P. Morgan Healthcare Conference

Upstream Bio (UPB): Reassessing Valuation After NASDAQ Biotechnology Index Inclusion and Sharp 3‑Month Rally

Simply Wall St.

Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?

Simply Wall St.

Upstream Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $51

THOMSON REUTERS

Upstream Bio Initiated at Outperform by LifeSci Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/UPB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":8.75,"timestamp":1771016400000,"preClose":12.8,"halted":0,"volume":6503631,"hourTrading":{"tag":"盘后","latestPrice":8.8,"preClose":8.75,"latestTime":"19:56 EST","volume":50441,"amount":441161.2368,"timestamp":1771030613804,"change":0.05,"changeRate":0.005714,"amplitude":0.025143},"delay":0,"changeRate":-0.31640625000000006,"floatShares":31417476,"shares":54038591,"eps":-2.274,"marketStatus":"Closed","change":-4.05,"latestTime":"02-13 16:00:00 EST","open":12.69,"high":12.69,"low":8.52,"amount":63617113.657704,"amplitude":0.325781,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.274,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":5,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":12.8,"preHourTrading":{"tag":"盘前","latestPrice":12.66,"preClose":12.8,"latestTime":"09:29 EST","volume":374,"amount":4696.237964,"timestamp":1770992999912,"change":-0.14,"changeRate":-0.010938,"amplitude":0.045313},"postHourTrading":{"tag":"盘后","latestPrice":8.8,"preClose":8.75,"latestTime":"19:56 EST","volume":50441,"amount":441161.2368,"timestamp":1771030613804,"change":0.05,"changeRate":0.005714,"amplitude":0.025143},"volumeRatio":2.234044,"impliedVol":2.0853,"impliedVolPercentile":0.8987},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-28.15%","roe":"-40.80%","lyrEps":-5.58348,"volumeRatio":2.234044,"shares":54038591,"dividePrice":0,"high":12.69,"amplitude":0.325781,"preClose":12.8,"low":8.52,"week52Low":5.14,"pbRate":"1.25","psRate":"168.93","week52High":33.68,"institutionHeld":0,"latestPrice":8.75,"eps":-2.274,"divideRate":0,"volume":6503631,"delay":0,"ttmEps":-2.274,"open":12.69,"prevYearClose":27.15,"prevWeekClose":26.2,"prevMonthClose":31.08,"prevQuarterClose":27.15,"fiveDayClose":26.2,"twentyDayClose":30.9,"sixtyDayClose":25.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1766034000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2026-02-12","current":-3.847845,"percent":0.907186,"low":-36.237602,"twenty":-13.972769,"median":-10.124466,"eighty":-7.496584,"high":-5.184222,"avg":-12.127685,"sd":6.703044,"marketCap":793826901},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-05","current":-12.264416,"twenty":-16.306728,"median":-9.154334,"eighty":-7.402392,"marketCap":1499030514},{"date":"2025-12-12","current":-12.145044,"twenty":-16.258549,"median":-9.253501,"eighty":-7.413262,"marketCap":1484440094},{"date":"2025-12-19","current":-13.201711,"twenty":-16.238474,"median":-9.412348,"eighty":-7.419454,"marketCap":1613592327},{"date":"2025-12-26","current":-13.38298,"twenty":-16.206354,"median":-9.577476,"eighty":-7.422171,"marketCap":1635748149},{"date":"2026-01-02","current":-12.003565,"twenty":-15.686418,"median":-9.608438,"eighty":-7.426849,"marketCap":1467147745},{"date":"2026-01-09","current":-12.175992,"twenty":-13.691713,"median":-9.623919,"eighty":-7.437719,"marketCap":1488222796},{"date":"2026-01-16","current":-13.661516,"twenty":-14.223893,"median":-9.706483,"eighty":-7.459459,"marketCap":1669792461},{"date":"2026-01-23","current":-14.055003,"twenty":-14.055003,"median":-9.763246,"eighty":-7.459459,"marketCap":1717886807},{"date":"2026-01-30","current":-13.679201,"twenty":-14.055003,"median":-9.837934,"eighty":-7.487886,"marketCap":1671954005},{"date":"2026-02-06","current":-11.495127,"twenty":-13.997527,"median":-9.967119,"eighty":-7.498759,"marketCap":1405003366},{"date":"2026-02-12","current":-6.494747,"twenty":-13.972769,"median":-10.124466,"eighty":-7.496584,"marketCap":793826901}],"updateTime":1771028529308},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611698921","title":"Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2611698921","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611698921?lang=en_us&edition=fundamental","pubTime":"2026-02-13 23:45","pubTimestamp":1770997500,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc.  shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials.Over the last few days, the stock has plunged more than 54%.The decline follows a report highlighting the company’s results for its asthma treatment.The VALIANT trial demonstrated statistically significant reductions in the annualized asthma exacerbation rate  of 56% for the 100 mg every 12 weeks dosing compared to placebo.Additionally, the drug showed improvements in lung function and was well-tolerated, with over 90% of eligible patients transitioning to the long-term extension study.The broader market experienced a mixed performance on the previous trading day, with the Healthcare sector remaining flat, gaining 0.00%. Upstream Bio’s decline comes as the broader market showed resilience, suggesting that company-specific factors may be influencing the stock’s movement.Analyst Matt Phipps wrote that shares trading down almost 50% ‘is overdone’, as some i","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Boy-Using-Nasal-Spray-Bottle---Allergy-C.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Boy-Using-Nasal-Spray-Bottle---Allergy-C.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50614440/upstream-bios-selloff-may-be-overdone-but-analyst-highlights-asthma-drugs-competitive-edge-concerns","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50614440/upstream-bios-selloff-may-be-overdone-but-analyst-highlights-asthma-drugs-competitive-edge-concerns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","BK4217","TSLP","SMA","UPB"],"gpt_icon":0},{"id":"2611215711","title":"Evercore ISI Remains a Buy on Upstream Bio, Inc. (UPB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611215711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611215711?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:16","pubTimestamp":1770988611,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Upstream Bio, Inc. yesterday and set a price target of $40.00. Kasimov covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-upstream-bio-inc-upb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-upstream-bio-inc-upb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610153951","title":"Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2610153951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610153951?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:35","pubTimestamp":1770824123,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on UPB stock, giving a Buy rating today. Kate Dellorusso has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-tezspire‑comparable-efficacy-convenient-q12w-dosing-and-solid-cash-runway-supporting-verekitugs-long‑term-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-tezspire‑comparable-efficacy-convenient-q12w-dosing-and-solid-cash-runway-supporting-verekitugs-long‑term-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB"],"gpt_icon":0},{"id":"2610953407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953407?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:04","pubTimestamp":1770818685,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","SHPU","HL","HOOG","LYFT","THC","GILD","NEM","DTIL","UPB","TMUS","AMZN","NET","CEG","RIO.AU","SCCO","BWA","BETA","ROBN","BHP.AU","MCD","AMZU","CDE","R","TPST","FCX","PSN","HOYY","AMZZ","KHC","FRSH","AMZW","AZYY","QXO","CURB","HNGE","AMZD","HOOW","RIO.UK","HOOD","SHOP","MAT","USAW.SI","AVTR","GFS","AMZY","GLTO","HUM","AU"],"gpt_icon":0},{"id":"2610144930","title":"Upstream Bio Reports Mixed Results in Phase 2 Data for Asthma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610144930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610144930?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:12","pubTimestamp":1770815520,"startTime":"0","endTime":"0","summary":"Upstream Bio said a Phase 2 clinical trial for its respiratory-disease treatment met its primary endpoint in two dosing regimens, but that a third treatment group didn't see consistent improvements.The clinical-stage biotechnology company said the Phase 2 Valiant clinical trial, evaluating verekitug in adults with severe asthma, showed that verekitug reduced asthma attacks and improved lung function with dosing of 100 milligrams every 12 weeks and 400 mg every 24 weeks.For another low-dose treatment group, 100 milligrams every 24 weeks, Upstream said there were positive effects but not consistent improvements toward the trials' endpoints.Shares were down about 22% to $21.83 in premarket trading.Asthma is a chronic condition in which the airways become inflamed and narrowed, making it hard to breathe.Upstream said it will now use the data collected from the previous trials to inform its decisions for the following phase 3 trial, for which it says planning has already begun.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610320229","title":"Upstream Bio Shares Plunge 20% Premarket After Co Reports Mid-Stage Asthma Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610320229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610320229?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:38","pubTimestamp":1770813532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610932860","title":"BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932860?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:10","pubTimestamp":1770811808,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU0312595415.SGD","LU0498741890.SGD","LU0056508442.USD","LU0882574055.USD","LU1127390331.HKD","SG9999017495.SGD","LU0498741114.HKD","LU1935043536.SGD","LU1732799900.SGD","IE00B775H168.HKD","BK4554","BK4209","LU2168564065.EUR","IE00B775SV38.USD","LU0345770993.USD","LU2065171311.SGD","IE00B19Z3B42.SGD","NEM","LU2362541273.HKD","LU1223082519.USD","LU1267930730.SGD","LU1585245621.USD","LU2487616109.SGD","MRNA","LU1496350502.SGD","LU2211815571.USD","LU0203202063.USD","LU1691799644.USD","LU2746668974.SGD","LU0683600562.USD","BK4538","HOOW","LU0055631609.USD","LU2106854487.HKD","LU0251132253.USD","LU2452424414.USD","LU1914381329.SGD","LU0211331839.USD","SG9999001077.SGD","LU0114720955.EUR","MAT","IE00B1XK9C88.USD","LU0302445910.USD","BK4588","BK4533","LU0310799852.SGD","LU1066051498.USD","LU1815333072.USD","LU2023250504.SGD","LU2092937148.SGD","IE000KEQY171.SGD","LU2083900584.USD","LU0724617625.USD","SG9999015945.SGD","LU2133065610.SGD","HODU","LU0323591593.USD","LU1839511570.USD","LU1934455277.USD","IE00B19Z8X17.USD","IE00B4YYXB79.USD","LU2065170008.USD","IE00BWXC8680.SGD","IE00B19Z8W00.USD","LU0265550359.USD","LU0820561909.HKD","LU2764262908.HKD","IE00B7KXQ091.USD","LU2764263203.CNY","IE00BMPRXQ63.HKD","LU0640476718.USD","SG9999018865.SGD","LU0820562030.AUD","LU2750360641.GBP","LU2250418816.HKD","BK4190","LU2468319806.SGD","LU1551013342.USD","LU1935042215.USD","HL","LU0980610538.SGD","IE00BK4W5L77.USD","LU1046421795.USD","SG9999014914.USD","SGXZ81514606.USD","LU0266013472.USD","LU1814569148.SGD","CURB","LU0528227936.USD","BK4154","BK4210","LU2498475776.HKD","LU0788108826.HKD","MCD","LU2361045086.USD","LU1852331112.SGD","LU0345768153.USD","LU0648000940.SGD","SBSW","LU2896262040.SGD","IE00B4JS1V06.HKD","LU0072462426.USD","LU0912757837.SGD","LU0096362180.USD","LU0466842654.USD","BK4592","LU1366333091.USD","IE00B3S45H60.SGD","LU0642271901.SGD","LU2461242641.AUD","BK4547","LU2471134523.USD","SG9999014880.SGD","LU2463028550.USD","LU1935043023.USD","LU0096364046.USD","LU1983260115.SGD","BK4121","IE0005OL40V9.USD","BK4539","LU2108987350.USD","LU0289941410.SGD","HUM","LU0648001328.SGD","BK4578","LU0861579265.USD","AMZU","LU0965508806.USD","LU1366192091.USD","LU2362540622.SGD","LU1066051811.HKD","SGXZ23171101.USD","IE00BZ1G4Q59.USD","LU1989764664.SGD","LU1035775433.USD","HOYY","LU1093756325.SGD","BK4220","HOOI","LU1803068979.SGD","LU2324357040.USD","LU2756315664.SGD","LU2360032135.SGD","LU2213496289.HKD","LU2023251221.USD","LU1718418525.SGD","LU0348723411.USD","LU1037948541.HKD","LU2028103732.USD","IE00BFSS8Q28.SGD","LU0964807845.USD","LU0630314457.HKD","BK4610","IE00BJLML261.HKD","LU0456854461.SGD","SGXZ99366536.SGD","LU0029864427.USD","LU0942090050.USD","LU0345780521.USD","LU0330918003.SGD","LU1934455194.USD","SGXZ31699556.SGD","LU1791710582.SGD","LU0210528500.USD","LU0795875169.SGD","LU1430594728.SGD","LU1435385759.SGD","LU0345780281.USD","LU0157215616.USD","HK0000914686.HKD","USAW.SI","LU0320765992.SGD","IE000W1ABFV2.USD","LU2347655156.SGD","LU1201861165.SGD","LU2063271972.USD","EXK","LU0234572021.USD","LU0308772762.SGD","BK4559","LU0943347566.SGD","IE00B5TLWC47.USD","LU1064131342.USD","LU2242650005.HKD","LU0390134368.USD","LU1169589451.USD","LU2505996509.AUD","LU2097829019.USD","LU2430703178.SGD","LU1069347547.HKD","LU0266512473.USD","LU1674673691.USD","LU2247934214.USD","IE0034235303.USD","BK4116","LU0345768740.USD","LU2077746001.SGD","LU1804176565.USD","LU2271345857.HKD","LU2361044865.SGD","LU1069344957.HKD","LU1119994496.HKD","LU1720051108.HKD","BK4548","BK4604","LU2087621335.USD","BK4551","LU0158827948.USD","LU2279689827.SGD","BK4532","AVTR","LU0724618789.USD","LU1974910355.USD","SG9999014005.SGD","LU1868836591.USD","LU0353189763.USD","LU0345770308.USD","IE00BJTD4V19.USD","SG9999002224.SGD","LU0345774631.USD","LU1988902786.USD","LU2236285917.USD","BK4097","AMZW","LU2417539215.USD","LU0170899867.USD","BK4139","BK4543","LU1074936037.SGD","LU1116320901.HKD","IE00BFSS7M15.SGD","BK4023","LU1145028129.USD","LU2265009873.SGD","LU1093756168.USD","LU1868837136.USD","LU0011850046.USD","LU1629891620.HKD","LU0965509101.SGD","LU0719512351.SGD","BK4017","HOOZ","LU0654597011.USD","LU1674673428.USD","AMZZ","BK4581","LU1116320737.USD","LU0823411888.USD","LU0215105999.USD","BK4612","LU2462611646.USD","LU1917777945.USD","LU0957791311.USD","IE00B1BXHZ80.USD","LU2089284900.SGD","LU0300736492.USD","BK4534","NET","IE0004445015.USD","LU0345769631.USD","LU1551013425.SGD","LU2326559502.SGD","LU0127658192.USD","SG9999004303.SGD","IE00BJJMRX11.SGD","IE00B3T34201.USD","IE00B3SWFQ91.USD","BK4524","LU0345781412.USD","LU0070302665.USD","LU0965509283.SGD","IE0003U64NQ7.SGD","LU0234570918.USD","IE000ITXATA3.USD","LU0130103400.USD","LU2211817866.USD","SG9999015978.USD","LU0868494708.USD","LU0278409577.USD","LU2430703251.USD","LU0310800379.SGD","LU2065169927.USD","IE00BJTD4N35.SGD","BK4527","HOOD","LU2347655073.USD","LU2168564149.EUR","LU1235294995.USD","LU0795875086.SGD","IE0002270589.USD","IE00B19Z9505.USD","IE0004445239.USD","SG9999014013.SGD","IE00BN29S564.USD","LU0882574139.USD","BK4570","LU0107464264.USD","LU0154236417.USD","LU1880398471.USD","LU2023250330.USD","LU1316542783.SGD","LU0788109477.HKD","LU0208291251.USD","LU0889565916.HKD","LU2286300806.USD","LU0267386448.USD","LU2089984988.USD","LU0985320562.USD","LU0965509010.AUD","LU0079474960.USD","BK4122","LU0354030511.USD","LU1989764748.USD","LU1861127337.USD","HOOY","LU0149725797.USD","LU2420271590.USD","LU0238689110.USD","LU0109391861.USD","LU0353189680.USD","IE00BFXG0V08.USD","LU1223083913.SGD","IE0009356076.USD","SG9999014906.USD","LU0345769128.USD","LU2750360997.AUD","LU0823434740.USD","LU1037948897.HKD","LU0109394709.USD","LU0061474705.USD","BK4598","LU2456880835.USD","LU2602419157.SGD","LU0708995401.HKD","LU2471134796.USD","LU1883866441.USD","LU2505996681.GBP","LU0211328371.USD","LU1261432733.SGD","AMZY","LU0368265764.SGD","LU2471134952.CNY","LU0496367417.USD","LU2462157665.USD","LU2237957811.SGD","LU0823434583.USD","LU0080751232.USD","LU1934455863.HKD","BK4022","IE0004091025.USD","LU1323610961.USD","LU1791710400.SGD","LU0162691827.USD","BK4503","LU2089283258.USD","LU0128525929.USD","GILD","LU2756315318.SGD","BK4561","LU0708994859.HKD","IE00BQXX3F31.USD","LU2168564495.EUR","LU0689472784.USD","LU1066053197.SGD","LU2054465674.USD","IE00BK4W5M84.HKD","LU0820561818.USD","LU0612318385.USD","LU0787776722.HKD","LU1732800096.USD","LU1548497426.USD","LU0316494557.USD","LU1223082196.USD","LU1868836757.USD","LU1244550494.USD","BK4104","AU","BK4613","LU0097036916.USD","LU0612318971.USD","LYFT","LU2357305700.SGD","LU0289960550.SGD","LU2361044949.HKD","LU1035773651.USD","LU0289739699.SGD","SG9999018857.SGD","BK4535","LU0048584097.USD","LU2362541513.USD","SVM","LU1066051225.USD","IE00BYQQ9H92.USD","UPB","HK0000914660.USD","LU0072461881.USD","LU0203201768.USD","LU0823416689.USD","SG9999014898.SGD","LU2381873111.SGD","LU1861558580.USD","LU2720916845.USD","GB00BDT5M118.USD","LU1778281490.HKD","LU1232071149.USD","LU0265550946.USD","LU0726765562.USD","LU2111349929.HKD","BK4522","BK4585","QXO","SGXZ51526630.SGD","GFI","IE00BMPRXR70.SGD","LU2552382132.HKD","LU2275660780.HKD","LU1935042488.USD","LU0053671581.USD","LU1244550577.SGD","LU0342679015.USD","IE000YTNTUN2.SGD","IE00B19Z3581.USD","IE00BJJMRY28.SGD","LU1883839398.USD","LU2125154778.USD","LU0354030438.USD","LU0672654240.SGD","LU0058720904.USD","CDE","LU0823421416.USD","IE00B5949003.HKD","HOOG","LU0053666078.USD","LU1823568750.SGD","IE0009G5SDU7.USD","LU1880398554.USD","FRSH","LU0109392836.USD","SG9999001143.SGD","AMZD","LU2764263039.SGD","SG9999015986.USD","BK4230","BK4501","BK4507","BK4607","LU2242649171.HKD","LU2543165471.USD","HOOX","LU0175139822.USD","LU2237438978.USD","LU0061474960.USD","LU2552382058.USD","LU0345774391.USD","IE00BQXX3D17.EUR","LU1267930573.SGD","LU2860962120.EUR","LU2746668461.USD","LU0320765489.SGD","AZYY","IE0004086264.USD","LU0256863902.USD","LU1868836914.USD","LU2592432038.USD","LU0210536198.USD","LU0082616367.USD","LU0211327993.USD","LU0456855351.SGD","LU0889565833.HKD","IE00B7SZLL34.SGD","LU0276348264.USD","BETA","LU0788109121.HKD","LU2092627202.USD","LU0417517546.SGD","LU2471134879.HKD","IE00BKVL7J92.USD","LU0345780950.USD","LU2552382215.SGD","BK4187","LU1280957306.USD","LU2430703095.HKD","LU0210533765.USD","BK4504","LU1430597077.USD","LU0266512127.USD","BK4579","LU1084165304.USD","LU1267930490.SGD","BK4583","LU1720051017.SGD","LU1169590202.USD","LU1571399168.USD","LU2403377893.USD","LU1633808545.USD","LU0061475181.USD","LU0077335932.USD","LU1201861249.SGD","SG9999014021.USD","LU0868494617.USD","LU2125154935.USD","LU1935042991.SGD","LU2168563687.JPY","LU2065171402.SGD","LU2168564222.USD","LU0198837287.USD","BK4560","LU1496350171.SGD","BK4231","IE00BMPRXN33.USD","LU1244550221.USD","BK4596","LU0158827781.USD","LU0823421333.USD","LU0130102774.USD","LU2264538146.SGD","LU1429558221.USD","SG9999015952.SGD","LU1023059493.AUD","BK4550","LU1868837300.USD","BK4566","IE00BKPKM429.USD","IE00BKDWB100.SGD","LU0314104364.USD","ROBN","LU2360106780.USD","LU2317271919.USD","LU0070217475.USD","BK4568","IE0001KFT4U8.USD","LU0256863811.USD","LU2237957902.USD","LU0320765059.SGD","LU2087625088.SGD","LU0786609619.USD","LU0494093205.USD","LU0300736062.USD","SG9999000418.SGD","LU1861559042.SGD","IE00BSNM7G36.USD","LU1153585028.USD","LU0075056555.USD","SG9999002232.USD","IE00BQXX3C00.GBP"],"gpt_icon":0},{"id":"2610934931","title":"Upstream Bio Reports Positive Phase 2 Severe Asthma Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934931","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934931?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:58","pubTimestamp":1770811126,"startTime":"0","endTime":"0","summary":"An announcement from Upstream Bio, Inc. ( ($UPB) ) is now available. On February 11, 2026, Upstream Bio reported positive top-line results from its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/upstream-bio-reports-positive-phase-2-severe-asthma-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/upstream-bio-reports-positive-phase-2-severe-asthma-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610939922","title":"BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610939922","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610939922?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:29","pubTimestamp":1770809384,"startTime":"0","endTime":"0","summary":"BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in midstage study** Shares of drug developer Upstream Bio UPB.O rise 20% to $32.64 in premarket trading** Company says its experimental asthma drug, Verekitug, reduced severe asthma attacks in a midstage study** The drug reduced yearly asthma flareups by 56% at a lower dose and 39% at a higher dose, and improved lung function - UPB** Side-effects were similar to earlier studies; over 90% of eligible patients entered a longterm extension study, company says** UPB plans latestage trials in severe asthma and chronic sinus disease after talks with regulators** Shares up ~65% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610936578","title":"Upstream Bio Inc - Verekitug Well Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936578?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610936506","title":"Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936506?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610365179","title":"Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365179?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610672247","title":"Upstream Bio Announces Top-Line Results from Phase 2 VALIANT Trial of Verekitug in Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672247?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:00","pubTimestamp":1770764411,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. announced that it will report top-line results from the Phase 2 VALIANT trial of verekitug, a thymic stromal lymphopoietin  receptor antagonist in development for severe asthma, on February 11, 2026. The VALIANT trial is a global, randomized, double-blind, placebo-controlled clinical study that evaluated the safety and efficacy of verekitug in 478 patients with severe asthma. The webcast presenting the results will be accessible on the company’s website, with a replay available following the event. The results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL8vYNTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","UPB","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2604437913","title":"Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604437913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604437913?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:10","pubTimestamp":1768587040,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Upstream Bio, Inc. (UPB – Research Report) and BioNa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-bionano-genomics-bngo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-bionano-genomics-bngo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4137","BK4575","LABU","XBI","BK4139","BK4585","BK4121","BNGO","LU0128526141.USD","BK4588","BK4581","HCSG","UPB","LU0029874061.USD"],"gpt_icon":0},{"id":"2602514234","title":"Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514234?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:04","pubTimestamp":1768219469,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps . Verekitug met its primary endpoint, achieving a reduction in nasal polyp score  of -1.8 , and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% . The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1db9bs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2601725885","title":"Upstream Bio CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601725885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601725885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614415,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT. The company's Chief Executive Officer, Dr. Rand Sutherland, will deliver the presentation, which will be available via live webcast on the Investors section of Upstream Bio's website. A replay will also be accessible following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL34xFQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","UPB","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2593941230","title":"Upstream Bio (UPB): Reassessing Valuation After NASDAQ Biotechnology Index Inclusion and Sharp 3‑Month Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2593941230","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593941230?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:15","pubTimestamp":1766499309,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) just earned a spot in the NASDAQ Biotechnology Index, a visibility upgrade that can quietly reshape its investor base, trading volume, and how the market values its pipeline.\nSee our latest analysis for Upstream Bio.\nThat index inclusion lands on top of already strong momentum, with the share price at $30.43 and an 86.92% 3 month share price return that suggests investors are re-rating its risk and growth profile rather than just reacting to a one day move.\nIf this kind of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-reassessing-valuation-after-nasdaq-biotechn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-reassessing-valuation-after-nasdaq-biotechn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NBI","QLD","MNQmain","TQQQ","UPB","USAW.SI","USJW.SI","SQQQ","BK4139","PSQ",".IXIC","NVIW.SI","QID","NQmain","TSYW.SI"],"gpt_icon":1},{"id":"2592146266","title":"Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592146266?lang=en_us&edition=fundamental","pubTime":"2025-12-20 21:17","pubTimestamp":1766236664,"startTime":"0","endTime":"0","summary":"Earlier this week, Mizuho Securities analyst Joseph Catanzaro initiated coverage on Upstream Bio with a buy rating, signaling fresh Wall Street attention on the biotech name.\nThis coverage launch brings Catanzaro’s recent track record, where fewer than half of his calls were successful but still generated an 8.5% average return, into focus for investors assessing the endorsement’s weight.\nNext, we’ll examine how this new Mizuho coverage and Catanzaro’s track record might influence Upstream...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/does-mizuhos-new-coverage-of-upstream-bio-upb-reframe-the-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/does-mizuhos-new-coverage-of-upstream-bio-upb-reframe-the-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MFG","BK4139","UPB","BK4207"],"gpt_icon":0},{"id":"2592296819","title":"Upstream Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $51","url":"https://stock-news.laohu8.com/highlight/detail?id=2592296819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592296819?lang=en_us&edition=fundamental","pubTime":"2025-12-18 12:07","pubTimestamp":1766030833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO00L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2588605370","title":"Upstream Bio Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588605370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588605370?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:04","pubTimestamp":1764680640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 08:04 ET (13:04 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}